Program
Methylprednisolone
Also written as “methylprednisolone”, “Vasopressin; Methylprednisolone; Hydrocortisone” and “Methylprednisolone/prednisolone”.
Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Myeloma · Diabetes Insipidus · Myopathies, Structural, Congenital · Gaucher Disease, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 40 open or running | phase 4since May 27, 2005 | May 27, 2005 | none ahead |
| Pfizer | 40 open or running | phase 1since Dec 13, 2010 | Dec 13, 2010 | none ahead |
| Oncotherapeutics | 22 open or running | phase 1since Nov 7, 2023 | Nov 7, 2023 | Apr 1, 2027phase 1 · NCT06225310 |
| amsterdam-molecular-therapeutics | 10 open or running | phase 3since Apr 30, 2009 | Apr 30, 2009 | none ahead |
| Astellas Pharma | 11 open or running | phase 2since Jun 30, 2025 | Jun 30, 2025 | Oct 31, 2027phase 2 · NCT07052929 |
| Bristol-Myers Squibb | 10 open or running | phase 2since May 4, 2016 | May 4, 2016 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 4since Jan 3, 2019 | Jan 3, 2019 | none ahead |
| Eli Lilly | 11 open or running | phase 2since May 11, 2020 | May 11, 2020 | Feb 2027phase 2 · NCT04411654 |
| Sun Pharmaceutical Industries | 10 open or running | phase 2since Oct 31, 2016 | Oct 31, 2016 | none ahead |
Also a collaborator on its studies: Incyte, elan-pharmaceuticals and the-clinical-trial-company.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 27, 2005First study: phase 4 study in Multiple Sclerosis, Relapsing-RemittingNew to BiogenBiogen · NCT00112034 · 350 enrolled · United States
- Jun 25, 20072 phase 4 studies in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT00493116, NCT00492466
- Apr 30, 2009amsterdam-molecular-therapeutics's first study: phase 3 study in Hyperlipoproteinemia Type INew to amsterdam-molecular-therapeuticsamsterdam-molecular-therapeutics · NCT00891306 · 5 enrolled · Canada
- Feb 17, 2010Phase 2 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT01071083 · 175 enrolled · United States, Germany, Spain
- Dec 13, 2010Pfizer's first study: phase 1 study in Biological AvailabilityNew to PfizerPfizer · NCT01267201 · 24 enrolled · Singapore
- Jul 25, 20113 phase 1 studiesPfizer · NCT01405170, NCT01405157, NCT01405131
- May 4, 2016Bristol-Myers Squibb's first study: phase 2 study in Carcinoma, Renal CellNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02763761 · United States
- Oct 31, 2016Sun Pharmaceutical Industries's first study: phase 2 study in Prostatic NeoplasmsNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT02962284 · 20 enrolled
- Jan 3, 2019Chong Kun Dang Pharmaceutical's first study: phase 4 study in Kidney TransplantNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03794492 · 169 enrolled · Korea, Republic of
- May 11, 2020Eli Lilly's first study: phase 2 study in Gaucher DiseaseNew to Eli LillyEli Lilly · NCT04411654 · 7 enrolled · United States, United Kingdom
- Nov 7, 2023Oncotherapeutics's first study: phase 1 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT06225310 · 30 planned · United States
- Jan 8, 2024Early phase 1 study in Multiple MyelomaOncotherapeutics · NCT06209606 · 30 planned · United States
- Jun 30, 2025Astellas Pharma's first study: phase 2 study in Myopathies, Structural, CongenitalNew to Astellas PharmaAstellas Pharma · NCT07052929 · 9 planned · United States, Canada
Ahead
- Feb 2027Primary completion: phase 2 study in Gaucher DiseaseEli Lilly · NCT04411654
- Apr 1, 2027Primary completion: phase 1 study in Multiple MyelomaOncotherapeutics · NCT06225310
- Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07052929Myopathies, Structural, Congenital · United States, Canada | 2 | Recruiting | Astellas Pharma | Oct 31, 2027 | 9 |
| NCT06209606Multiple Myeloma · United States | Early 1 | Recruiting | Oncotherapeutics | May 2026 | 30 |
| NCT06225310Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Apr 1, 2027 | 30 |
| NCT04411654Gaucher Disease · United States, United Kingdom | 2 | Active, not recruiting | Eli Lilly | Feb 2027 | 7 |
| NCT03794492Kidney Transplant · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | Jul 22, 2022 | 169 |
| NCT02962284Prostatic Neoplasms | 2 | Completed | Sun Pharmaceutical Industries | Mar 2018 | 20 |
| NCT02763761Carcinoma, Renal Cell · United States | 2 | Withdrawn | Bristol-Myers Squibb | Mar 31, 2017 | 0 |
| NCT01405170Lecithin Cholesterol Acyltransferase Deficiency | 1 | Withdrawn | Pfizer | Oct 28, 2011 | 0 |
| NCT01405157Fasting | 1 | Withdrawn | Pfizer | Feb 20, 2012 | 0 |
| NCT01405131Therapeutic Equivalency | 1 | Withdrawn | Pfizer | Feb 20, 2012 | 0 |
| NCT01267201Biological Availability · Singapore | 1 | Completed | Pfizer | Dec 2010 | 24 |
| NCT01071083Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Spain | 2 | Completed | Biogen | Nov 2011 | 175 |
| NCT00891306Hyperlipoproteinemia Type I · Canada | 3 | Completed | amsterdam-molecular-therapeutics | Aug 2010 | 5 |
| NCT00493116Multiple Sclerosis, Relapsing-Remitting · Australia, New Zealand | 4 | Completed | Biogen | Dec 2009 | 20 |
| NCT00492466Multiple Sclerosis, Relapsing-Remitting · Finland | 4 | Completed | Biogen | Aug 2006 | 14 |
| NCT00112034Multiple Sclerosis, Relapsing-Remitting · United States | 4 | Completed | Biogen | Jun 2006 | 350 |
How it is read
Names in the registry
- “methylprednisolone”, 16 entries
- “Methylprednisolone”, 7 entries
- “Vasopressin; Methylprednisolone; Hydrocortisone”, 1 entry
- “Methylprednisolone/prednisolone”, 1 entry
- “abiraterone acetate with Methylprednisolone”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, Relapsing-Remitting, 4 studies
- Multiple Myeloma, 2 studies
- Diabetes Insipidus, 1 study
- Myopathies, Structural, Congenital, 1 study
- Gaucher Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.